Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.33 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.33 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 5/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22012682 | 0.87 | AKR1C3 (0.33) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL22012683 | 0.79 | AKR1C3 (0.35) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL22012681 | 0.77 | AKR1C3 (0.40) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL15456907 | 0.69 | — | — | |
| SCHEMBL25033759 | 0.68 | AKR1C3 (0.33) | AKR1C3AKR1C2AKR1C1AKR1B10AKR1C4 | |
| SCHEMBL21726315 | 0.66 | SLC6A3 (0.56) | AKR1C3AKR1C2APPCYP2C19CYP3A4 | |
| SCHEMBL22012753 | 0.66 | NLRP3 (0.46) | — | |
| SCHEMBL25460830 | 0.63 | ELOVL1 (0.48) | CYP2C19HDAC1CFTR | |
| SCHEMBL3553242 | 0.62 | HDAC4 (0.62) | HDAC1 | |
| SCHEMBL2666199 | 0.62 | LMNA (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | AKR1C3 1379/4885AKR1C2 1398/4885AKR1C1 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.